A Phase 3 interventional study of acetaminophen and Rofecoxib in Osteoarthritis of the Knee, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-08-22.
Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing acetaminophen in Osteoarthritis, Knee — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis, Knee.
Among the 11 studies testing acetaminophen in Osteoarthritis, Knee, this one is the 4th largest by enrollment, is the only one that started in 1999, is one of 7 in phase 3, and was the 5th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →None of the 11 studies testing acetaminophen in Osteoarthritis, Knee is open now. The open studies under Osteoarthritis, Knee, anywhere →
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 403 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 300 across the 11 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Johnson & Johnson Consumer and Personal Products Worldwide, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.
31 studies in Osteoarthritis, Knee by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 31 finished, 13 (42%) have results posted.
Among the 31 studies in Osteoarthritis, Knee by Johnson & Johnson, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 1999, is one of 11 in phase 3, and was the 11th registered.
Johnson & Johnson’s Osteoarthritis, Knee studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing acetaminophen in Osteoarthritis, Knee, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 31 in Osteoarthritis, Knee:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare acetaminophen (Tylenol) with rofecoxib (Viox) for the treatment of Osteoarthritis of the Knee
An initial screening visit was performed in order to assess subject medical history and the potential eligibility of subjects. Following the initial screening visit, all potential subjects underwent a washout period from their usual arthritis medication and returned to the study center for a baseline visit to verify their eligibility.
At the completion of the baseline visit, all eligible subjects were randomly assigned to a treatment group and instructed on the dosing regimen for their assigned study medication.
Subjects returned to the study center for follow-up visits after Week 1 and Week 2 of treatment and a final visit after Week 4 of treatment or upon discontinuation from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP
Drug: acetaminophen
Rofecoxib: Capsules 12.5 mg, oral, C-904-1A
Drug: Rofecoxib
Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A
Drug: Rofecoxib
Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Also known as: Tylenol
Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Also known as: Viox
Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
Also known as: Viox
Change from Baseline in the Western Ontario and McMaster Universities (WOMAC) pain subscale score at week 4 in the per protocol study population.
Time frame: Four Weeks
Change from Baseline in the WOMAC pain subscale score
Time frame: Weeks 1 and 2
Change from baseline in the WOMAC stiffness and physical function subscale scores
Time frame: Weeks 1, 2 and 4
Investigator's impression of therapeutic response
Time frame: Weeks 1, 2, and 4
Subject's assessment of medication as an analgesic for the study knee joint
Time frame: Weeks 1, 2, and 4
Daily pain intensity differences from baseline
Time frame: Week 1
Investigator's global impression of therapeutic response
Time frame: Week 4
Subject's overall impression of the study medication
Time frame: Week 4
No study locations are listed for this record.
The record gives a start of Oct 1999, a primary completion of Oct 2000 and a completion of Oct 2000. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen
Johnson & Johnson Consumer and Personal Products Worldwide →